Piper Sandler Maintains Bullish $48 Price Target on Avalo Therapeutics (AVTX)

Core Insights - Avalo Therapeutics, Inc. is identified as a top long-term biotechnology stock with a significant upside potential of 167.86% based on a price target of $48 set by Piper Sandler analyst Yasmeen Rahimi [1][2]. Company Overview - Avalo Therapeutics focuses on developing treatments for immune-mediated inflammatory diseases, with its lead product candidate, AVTX-009, currently in a Phase 2 clinical trial for hidradenitis suppurativa [3]. - The company's pipeline includes additional assets such as quisovalimab and AVTX-008, which are aimed at modulating the immune system [3]. Analyst Perspective - Piper Sandler maintains a bullish outlook on Avalo, emphasizing confidence in the company's strategic direction and progress in its clinical pipeline, particularly in immune dysregulation therapies [2]. - Recent leadership changes, strategic collaborations, and the ability to meet development milestones have contributed to the positive sentiment surrounding Avalo [2].